<DOC>
	<DOCNO>NCT02301780</DOCNO>
	<brief_summary>Phase III two arm double-blinded randomised control trial examine effect prophylactic low-dose aspirin first-trimester pregnancy woman increase risk PET incidence severity disease</brief_summary>
	<brief_title>Combined Multi-marker Screening Treatment With Aspirin Pre-eclampsia Prevention</brief_title>
	<detailed_description>Screening Prevention Pre-eclampsia ( High Blood Pressure ) : Randomised Trial Aspirin Versus Placebo ( ASPRE ) Screening : All woman singleton pregnancy undergo routine screening aneuploidy invite participate screening study PET . Interventions : Participants screen high-risk develop PET randomise one 2 arm trial ( day screen within 1 week screen visit ) . Randomised participant advise start 150mg Aspirin/Placebo per night within 24 hour randomisation 36 week ' gestation sign labour commence . The maximum duration aspirin placebo intake 180 day . Key Inclusion Exclusion Criteria Inclusion criterion participant selection RCT Age &gt; 18 year , Singleton pregnancy , Live fetus 11-13 week gestation , High-risk preterm-PET 11-13 week algorithm combine maternal history characteristic , biophysical finding ( mean arterial pressure uterine artery Dopplers ) biochemical factor ( pregnancy associate plasma protein-A placental growth factor ) , English , Italian , Spanish , French , Dutch Greek speaking ( otherwise interpreter use ) , Informed write consent . Exclusion criterion Multiple pregnancy , Women take low-dose aspirin regularly ( administration must cease &gt; 28days prior randomisation ) , Pregnancies complicate major fetal abnormality identify 11-13 week assessment , Women unconscious severely ill , learn difficulty , serious mental illness , Bleeding disorder Von Willebrand 's disease , Peptic ulceration , Hypersensitivity aspirin already long term non-steroidal anti-inflammatory medication , Age &lt; 18 year , Concurrent participation another drug trial time within previous 28 day , Any reason clinical investigator think prevent potential participant comply trial protocol .</detailed_description>
	<mesh_term>Pre-Eclampsia</mesh_term>
	<mesh_term>Eclampsia</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Age &gt; 18 year Singleton pregnancies Live fetus 1113 week gestation , Highrisk pretermPET 1113 week algorithm combine maternal history characteristic , biophysical finding ( mean arterial pressure uterine artery Dopplers ) biochemical factor ( pregnancy associate plasma proteinA placental growth factor ) , English , Italian , Spanish , French , Flemish , Hebrew , Arabic Russian speaking ( otherwise interpreter use ) Informed write consent . Multiple pregnancy Women take lowdose aspirin regularly Pregnancies complicate major fetal abnormality identify 1113 week assessment Women unconscious severely ill , learn difficulty , serious mental illness , Bleeding disorder Von Willebrand 's disease Peptic ulceration Hypersensitivity aspirin already long term nonsteroidal anti inflammatory medication Age &lt; 18 year Concurrent participation another drug trial time within previous 28 day Any reason clinical investigator think prevent potential participant comply trial protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>